Accueil   Agenda - News   Toutes les news EVOTEC BIOLOGICS partners with ABL on development of broadly neutralising antibody against HIV

EVOTEC BIOLOGICS partners with ABL on development of broadly neutralising antibody against HIV

Hamburg, Germany, 08 June 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into an agreement with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry. This project has been 100% funded with Federal funds under a $ 318.5 m contract from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201700010I/ HHSN27200009.

 

Read the press release